See more : Arctic Blue Beverages AB (publ) (ARCTIC.ST) Income Statement Analysis – Financial Results
Complete financial analysis of Bio-Path Holdings, Inc. (BPTH) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bio-Path Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Yuan High-Tech Development Co., Ltd. (5474.TWO) Income Statement Analysis – Financial Results
- Proya Cosmetics Co.,Ltd. (603605.SS) Income Statement Analysis – Financial Results
- Eisai Co., Ltd. (4523.T) Income Statement Analysis – Financial Results
- Nocopi Technologies, Inc. (NNUP) Income Statement Analysis – Financial Results
- Mudrick Capital Acquisition Corporation II (MUDSU) Income Statement Analysis – Financial Results
Bio-Path Holdings, Inc. (BPTH)
About Bio-Path Holdings, Inc.
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.00K | 13.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 18.44K | 43.81K | 59.45K | 79.31K |
| Cost of Revenue | 178.00K | 178.00K | 161.00K | 151.00K | 230.00K | 426.00K | 0.00 | 0.00 | 201.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 20.11K | 37.77K | 43.88K | 55.42K |
| Gross Profit | -178.00K | -178.00K | -161.00K | -151.00K | -230.00K | -426.00K | 37.00K | 13.00K | -201.76K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -1.67K | 6.05K | 15.58K | 23.90K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 100.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -9.05% | 13.80% | 26.20% | 30.13% |
| Research & Development | 11.61M | 9.17M | 5.91M | 6.58M | 4.59M | 4.60M | 5.48M | 5.47M | 3.02M | 1.83M | 1.63M | 1.60M | 1.14M | 1.14M | 480.26K | 333.47K | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 4.11M | 4.74M | 4.53M | 4.33M | 4.11M | 3.38M | 3.52M | 3.01M | 2.46M | 2.72M | 1.63M | 986.10K | 0.00 | 704.88K | 1.31M | 587.16K | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 123.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 4.24M | 4.74M | 4.53M | 4.33M | 4.11M | 3.38M | 3.52M | 3.01M | 2.46M | 2.72M | 1.63M | 986.10K | 1.22M | 704.88K | 1.31M | 587.16K | 107.44K | 141.31K | 82.53K | 78.16K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 608.00K | 0.00 | 0.00 | 196.66K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 182.98K | 171.95K | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 15.84M | 13.90M | 10.44M | 10.91M | 8.69M | 7.98M | 9.00M | 8.49M | 5.48M | 4.54M | 3.27M | 2.58M | 2.37M | 1.85M | 1.97M | 1.09M | 107.44K | 141.31K | 82.53K | 78.16K |
| Cost & Expenses | 15.84M | 13.90M | 10.44M | 10.91M | 8.69M | 7.98M | 9.00M | 8.49M | 5.48M | 4.54M | 3.27M | 2.58M | 2.37M | 1.85M | 1.97M | 1.09M | 127.55K | 179.08K | 126.40K | 133.58K |
| Interest Income | 36.00K | 33.00K | 3.00K | 26.00K | 94.00K | 7.00K | 9.00K | 12.00K | 17.67K | 22.63K | 4.04K | 779.00 | 2.91K | 1.30K | 3.38K | 41.06K | 0.00 | 541.00 | 132.00 | 1.35K |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.94K | 13.08K | 17.62K | 13.26K |
| Depreciation & Amortization | 82.00K | 178.00K | 161.00K | 151.00K | 230.00K | 426.00K | 411.00K | 204.00K | 201.76K | 170.91K | 160.63K | 185.27K | 211.71K | 197.27K | 182.98K | 171.95K | 1.68K | 2.72K | 3.03K | 3.06K |
| EBITDA | -15.76M | -13.69M | -10.28M | -10.73M | -8.37M | -8.16M | -8.56M | -8.27M | -5.27M | -4.35M | -3.11M | -2.40M | -2.15M | -1.88M | -1.79M | -2.68M | -107.44K | -132.00K | -63.79K | -49.85K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -28,348.65% | -76,800.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -973.44% | -301.30% | -107.30% | -62.85% |
| Operating Income | -15.84M | -13.90M | -10.44M | -10.91M | -8.69M | -8.59M | -8.97M | -8.48M | -5.48M | -4.54M | -3.27M | -2.58M | -2.37M | -2.33M | -1.97M | -2.89M | -109.11K | -135.27K | -66.95K | -54.26K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -24,232.43% | -65,192.31% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -591.78% | -308.75% | -112.61% | -68.42% |
| Total Other Income/Expenses | -235.00K | 33.00K | 3.00K | 26.00K | 94.00K | 7.00K | 1.94M | 1.73M | 18.21K | 22.05K | 3.23K | -344.86K | 2.27K | -232.43K | 3.38K | 41.06K | 56.67K | -12.54K | -17.49K | -11.91K |
| Income Before Tax | -16.08M | -13.87M | -10.44M | -10.88M | -8.60M | -8.58M | -7.02M | -6.75M | -5.47M | -4.52M | -3.27M | -2.58M | -2.36M | -2.08M | -1.97M | -2.85M | -52.45K | -147.81K | -84.44K | -66.17K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18,981.08% | -51,923.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -284.44% | -337.37% | -142.02% | -83.43% |
| Income Tax Expense | 0.00 | -33.00K | -3.00K | -26.00K | -94.00K | -608.00K | -1.94M | -1.73M | 0.00 | -22.30K | -3.23K | -142.00 | -2.27K | 232.43K | 0.00 | 2.85M | 100.00 | 100.00 | 100.00 | 100.00 |
| Net Income | -16.08M | -13.84M | -10.44M | -10.86M | -8.51M | -8.58M | -7.02M | -6.75M | -5.47M | -4.52M | -3.27M | -2.58M | -2.36M | -2.08M | -1.97M | -2.85M | -52.55K | -147.91K | -84.54K | -66.27K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -18,981.08% | -51,923.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -284.99% | -337.60% | -142.19% | -83.56% |
| EPS | -33.64 | -38.03 | -31.04 | -56.44 | -64.02 | -287.54 | -278.69 | -291.26 | -243.61 | -202.50 | -183.04 | -174.15 | -175.57 | -172.91 | -186.06 | -277.22 | -3.84 | -14.13 | -13.71 | -10.75 |
| EPS Diluted | -33.64 | -38.03 | -31.04 | -56.44 | -64.02 | -287.54 | -278.69 | -291.26 | -243.61 | -202.50 | -183.04 | -174.15 | -175.57 | -172.91 | -186.06 | -277.22 | -3.84 | -14.13 | -13.71 | -10.75 |
| Weighted Avg Shares Out | 478.00K | 363.80K | 336.25K | 192.35K | 132.85K | 29.85K | 25.20K | 23.18K | 22.44K | 22.32K | 17.84K | 14.83K | 13.46K | 12.04K | 10.59K | 10.29K | 13.69K | 10.47K | 6.17K | 6.17K |
| Weighted Avg Shares Out (Dil) | 478.00K | 363.80K | 336.25K | 192.35K | 132.85K | 29.85K | 25.20K | 23.18K | 22.44K | 22.32K | 17.84K | 14.83K | 13.46K | 12.04K | 10.59K | 10.29K | 13.69K | 10.47K | 6.17K | 6.17K |
Bio Path Holdings Inc. (BPTH) CEO Peter Nielsen on Q1 2022 Results - Earnings Call Transcript
Bio Path Holdings Inc. (NASDAQ:BPTH ) Q1 2022 Results Conference Call May 17, 2022 8:30 AM ET Company Participants Peter Nielsen - President, CEO Anthony Price - SVP, Finance, Accounting & Administration Conference Call Participants Yi Chen - H.C. Wainwright...
Bio-Path Holdings to Announce First Quarter 2022 Financial Results on May 17, 2022
HOUSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a...
Why Bio-Path Holdings Shares Are Rising After Hours
Bio-Path Holdings Inc (NASDAQ: BPTH) shares are trading higher in Tuesday's after-hours session following the company's BP1003 data presentation at the 2022 American Association for Cancer Research Annual Meeting. Bio-Path presented a poster at the annual meeting titled .
Bio-Path Holdings Inc. (BPTH) CEO Peter Nielsen on Q4 2021 Results - Earnings Call Transcript
Bio-Path Holdings Inc. (BPTH) CEO Peter Nielsen on Q4 2021 Results - Earnings Call Transcript
Bio-Path Holdings to Present at the 2022 American Association for Cancer Research Annual Meeting
HOUSTON, March 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize™ liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation...
Bio-Path Holdings to Announce Full Year 2021 Financial Results on March 11, 2022
HOUSTON, March 04, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a...
Bio-Path Holdings to Present at H.C. Wainwright BioConnect 2022 Virtual Conference
HOUSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that Peter Nielsen, Chief Executive...
Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q3 2021 Results - Earnings Call Transcript
Bio-Path Holdings, Inc. (BPTH) CEO Peter Nielsen on Q3 2021 Results - Earnings Call Transcript
Bio-Path Holdings to Present Clinical Data at the 63rd Annual American Society of Hematology Annual Meeting
HOUSTON, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced an upcoming poster presentation at...
BPTH Stock: The Good News That Has BioPath Investors Smiling Today
BioPath (BPTH) stock is soaring higher on Tuesday after revealing an update from the FDA on its IND application for BP1002. The post BPTH Stock: The Good News That Has BioPath Investors Smiling Today appeared first on InvestorPlace.
Source: https://incomestatements.info
Category: Stock Reports